EGFR and colorectal carcinoma: Ahronian et al. (2015) has shown that the reactivation of the MAPK pathway confers cross-resistance to the combined RAF/EGFR or RAF/MEK inhibition in BRAF-mutant CRC and further demonstrated that the use of ERK inhibitor could overcome the resistance by suppressing the MAPK signalling.